Why Novavax's Pending COVID Vaccine Deal With the EU Raised Concerns

·3 min read

Novavax (NASDAQ: NVAX) is reportedly getting close to finalizing a major supply deal with the European Union. In this Motley Fool Live video recorded on May 5, Motley Fool contributors Keith Speights and Brian Orelli discuss why the biotech's pending EU deal has raised some concerns. Keith Speights: Reuters reported earlier this week that Novavax, the ticket there's end NVAX.